国产三级在线看完整版-内射白嫩大屁股在线播放91-欧美精品国产精品综合-国产精品视频网站一区-一二三四在线观看视频韩国-国产不卡国产不卡国产精品不卡-日本岛国一区二区三区四区-成年人免费在线看片网站-熟女少妇一区二区三区四区

儀器網(wǎng)（yiqi.com）歡迎您！

| 注冊(cè)2 登錄
網(wǎng)站首頁(yè)-資訊-話題-產(chǎn)品-評(píng)測(cè)-品牌庫(kù)-供應(yīng)商-展會(huì)-招標(biāo)-采購(gòu)-知識(shí)-技術(shù)-社區(qū)-資料-方案-產(chǎn)品庫(kù)-視頻

問(wèn)答社區(qū)

跑步追焦快門多少

拱鍛酌兔g 2014-11-09 09:45:01 335  瀏覽

  • 　

參與評(píng)論

全部評(píng)論(1條)

  • ken13536512101 2014-11-10 00:00:00
    跑得不是太快的話一般320以上都可以了，如果是運(yùn)動(dòng)會(huì)那種速度的話起碼500以上

    贊(13)

    回復(fù)(0)

    評(píng)論

熱門問(wèn)答

跑步追焦快門多少
　
2014-11-09 09:45:01 335 1
ZX快門與焦平面快門有何不同
攝影
2018-03-26 05:52:34 316 1
什么是鏡間快門和焦平面快門？
　
2017-10-08 22:58:32 438 1
拍攝跑步的人快門和光圈的參數(shù)？
如果要拍攝短跑（百米）和中長(zhǎng)跑的時(shí)候大概要用多少的快門？1/200可以嗎？我想拍出主體清晰背景模糊的~~~ 順便問(wèn)下如果想拍攝完全靜止的要用多少呢？ 如果拍攝運(yùn)動(dòng)的場(chǎng)景用快門優(yōu)先會(huì)不會(huì)造成曝光不足??？
2013-08-02 03:33:12 1534 2
什么是電子操控縱走焦平面快門
　
2009-03-11 21:34:23 337 2
每天跑步半個(gè)小時(shí)大概消耗多少卡路里？
我現(xiàn)在跑步··就是想知道能消耗多少脂肪！ 每天飲食注意點(diǎn)啥？
2013-04-02 04:39:40 1170 5
我跑步Z多可以吃多少atp
　
2017-09-26 11:47:27 448 2
搗鼓焦配合煤收縮一般多少
　
2015-03-11 11:29:42 525 1
佳能70D半按快門時(shí)沒(méi)有合焦聲音 如何解決？
　
2015-07-02 02:59:25 659 6
相機(jī)的快門1/多少多少那是什么意思？
2013-11-20 00:06:51 723 5
增加一檔亮度 快門增加多少
　
2012-06-16 13:36:14 512 2
二手單反快門多少是啥意思
　
2012-04-15 17:58:17 437 2
為什么運(yùn)動(dòng)手環(huán)在跑步機(jī)上也能夠測(cè)量跑步距離
　
2016-11-17 06:53:06 855 2
長(zhǎng)焦與短焦投影儀區(qū)別
　
2011-12-15 02:23:54 492 3
什么軟件，可以看圖片的快門多少，光圈多少，焦距多少？
　
2012-11-23 04:32:14 395 2
拍攝電視屏幕相機(jī)快門設(shè)置多少
　
2012-09-08 01:30:58 328 2
翻拍照片用多少光圈和快門
　
2012-09-24 18:46:02 558 2
翻譯 (好會(huì)追加分)
Internationalised Normal Ratio(INR) elevations and/or bleeding events have been reported in some patients taking warfarin(see Pharmacokinetic Properties' section). patients taking warfarin should be monitored regularly for changes in proth... Internationalised Normal Ratio(INR) elevations and/or bleeding events have been reported in some patients taking warfarin(see Pharmacokinetic Properties' section). patients taking warfarin should be monitored regularly for changes in prothrombin time or INR. patients shouldbe advised to seek medical advice promptly in the event of developing any eye symptoms or severe or persistent diarrhoea ， nausea vomiting or anorexia(see Pharmacokinetic Properties' section). These symptoms should be managed as clinically indicated. Randomised controlled trials have demonstrated that Iressa combined with doublet ， platinum-based cytotoxic chemotherapy in advanced NSCLC provides no added benefit over ther cytototxic in patientswho have previously received treatment with cytotoxic chemotherapy. In a phase I/II trial of IRESSA and radiation in paediatric patients， newly diagnosed with brain stem glioma or incompletely resected supratentorialmalignant glioma， 4 cases(1fatal) of CNS haemorrhages have been reported from trialwith IRESSA alone. There is no evidence to suggest any increased risk of cerebral haemorrhage in adult patients with NSCLC receiving IRESSA. Phase IIclinical trial data， where IRESSA and vinorelbine have been used concomitantly， indicate that Iressa may exacebate the neutropenic effctof vinorbine. Interaction with other medicinal products and other forms of interaction In vitro studies with human hepatic microsomes have shown that the metabolism of gefitinib is predomiantly via the CYP3A4 isoform of the hepatic cytochromeP-450 system. Gefitinib may be sxpected to interact with otehr drgs that induce， inhibit or are metabolised by this system. Gefitinib showed littl enzyme induction effect in animal studies and in vitro sutdies have shown that gefitinib has limited potentialto inhibit CYP2D6. The clinically or potentially significantclinical drug interactions between gefitinib and the following drugs/ durg classes are described below. Other Drugs that effect gefitinib Demonstrated interactions Drugs that inhaibit CYP3A4 co-administraion with itraconazole(a CYP3A4)resuulted in an 80% increase in the mean AUC of gefitinibin healthy volunteers. This increase may bbe clinically relevant since adverse experiences are related to dose and exposure. Although interaction studies with other CYP3A4 inhibitors have not been performed it is expected that drugs such as ketoconaxole， clotrimazole， ritonovir would also inhibit gefitinib metabolism. Drugs that Increase gastric pH In a trial in healthy volunteers co-adminstrationof drugs that cause significant sustined elevations in gastric pH>=5， resulted in a reduced mean gefitinib AUC by 47%. This may reduce efficacy Rifampicin Co-administration with rifa mpicin(a known potent CYP3A4 inducer) in healthy volunteers reduced meangefitinib AUC by 83% of that without rifampicin. Theoretical interactions 展開
2008-12-12 05:01:36 337 1
辛追 是什么人?
　
2007-05-01 13:36:28 436 3

4月突出貢獻(xiàn)榜

推薦主頁(yè)

最新話題